Covid-19 roundup: Moderna has filed for vaccine use in children; Claiming leadership to combat Covid-19, US pledges to donate 500M doses of Pfizer/BioNTech vaccines through COVAX
Just days after Moderna’s vaccine was submitted for approval for use in children in the EU and Canada, the company has announced it has filed for emergency use authorization with the FDA for the administration in teens between 12 and 18.
Moderna announced in May that its Phase II/III study of the vaccine in adolescents met the primary endpoints in nearly 2,500 patients, showing an efficacy of 100% against severe symptomatic Covid-19. Because children are less likely to develop serious side effects, the trial also looked at milder cases than examined in the adult study. The study found that the vaccine was 93% effective at stopping mild cases 14 days after patients were dosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.